Other Events ·
On June 17, 2026, Apogee Therapeutics entered into an antibody discovery agreement and a contemporaneous license…
APGEApogee Therapeutics, Inc.
On June 17, 2026, Apogee Therapeutics entered into an antibody discovery agreement and a contemporaneous license agreement with Paragon Therapeutics, Inc. Paragon will generate and characterize monospecific antibody candidates directed to interleukin 31 receptor (IL-31R), with Apogee paying monthly research fees and potential CMC activity fees between $1.3 million and $2.0 million. Apogee acquired an exclusive, worldwide, royalty-bearing license to exploit antibodies discovered under the agreement, with potential milestone payments to Paragon totaling up to $23.25 million, including $5.25 million upon the first human dose in a Phase I trial. The agreement includes low-single digit royalties on net sales. Apogee operates in the biotechnology industry and develops therapeutic antibodies.